Scientific Advanced Biotherapeutics (SAB) is a regional Pharmaceutical company established to provides all regulatory, marketing, sales, distribution channels and supply chain management for the global pharma and biotech companies to in-license and commercialize FDA or EMA approved innovative pharmaceutics, biologics, and other healthcare solutions in the Middle East & North Africa regions (MENA). Where Scientific Advanced Biotherapeutics (SAB) provides multi-country access across a wide region with growing economies but complex regulations and access hurdles. Scientific Advanced Biotherapeutics (SAB) offers type of business model designed to provide the partners, we represent, with a full range of services and multiple functions to bring long term commercial excellence and build value to our licensed brands across multiple geographies. Our key success factors are driven by exceptionally talented teams granted with their proven track record and experience in the pharmaceutical industry regionally and globally. Scientific Advanced Biotherapeutics (SAB) team has competencies in areas of regulatory, medical, pharmacovigilance and commercial capabilities acquired through years of experience in multinational pharma. The team is also well-connected to a wide range of partners and key stakeholders in and out of the region, which offers a flexible approach to joint-ventures and partnerships. The areas of Ophthalmology, oncology, biological, genomics, rare diseases, medical devices, and other innovative healthcare products are current strategic focus for Scientific Advanced Biotherapeutics (SAB). Scientific Advanced Biotherapeutics (SAB) is usually looking for product portfolio that match unmet medical needs in the region, to help patients gain access to these much-needed medications.